Opioid-related hospitalizations due to heroin poisoning for 2006 and 2007 are not reported because there were fewer than 10 per year.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Chua IS, Leiter RE, Brizzi KT, et al. US National Trends in Opioid-Related Hospitalizations Among Patients With Cancer. JAMA Oncol. 2019;5(5):734–735. doi:10.1001/jamaoncol.2019.0042
Opioids are routinely prescribed for cancer-related pain, but little is known about the prevalence of opioid-related hospitalizations among patients with cancer. Opioid addiction among these patients has been estimated to be as high as 7.7%,1 but our understanding of opioid misuse among patients with cancer is based on small, preliminary studies.2 In light of the wider opioid epidemic, oncologists and palliative care clinicians frequently balance providing patients with legitimate access to opioids while protecting them and the general public from the risks associated with prescribing these medications.3
We examined trends and risk factors of opioid-related hospitalizations among patients with cancer between January 1, 2006, and December 31, 2014, using the US National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP).4 The database contained deidentified patient information and was deemed exempt from institutional review by the Partners Healthcare Human Research Committee. All analysis was conducted between December 2017 and September 2018. Our primary outcome was the number of opioid-related hospitalizations among adults with cancer (≥18 years old). We identified opioid-related hospitalizations using the International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes for heroin poisoning, opioid poisoning, and opioid dependence or abuse in the primary diagnosis field.5 We identified these patients using ICD-9 codes (140.0-239.9, 258.01-258.03, 789.51), while excluding conditions that rarely require opioids for pain control. We excluded the following: carcinomas in situ, benign neoplasms, hematologic cancers in remission, macroglobulinemia, polycythemia vera, essential thrombocythemia, and nonmelanoma skin cancers.
A multivariable logistic regression model evaluated the association between opioid-related hospitalizations and age, sex, race/ethnicity, primary insurance type, median household income quartile, hospital type, geographic region, alcohol abuse, drug abuse, depression, psychotic disorder, comorbidities, and year of hospital discharge. Comorbidities were identified using the Elixhauser comorbidity software from HCUP4 but excluded alcohol abuse, depression, drug abuse, metastatic cancer, lymphoma, psychotic disorder, and solid tumors without metastasis since these were analyzed independently. Weighted frequencies, proportions, and 95% confidence intervals (CIs) were calculated to reflect national estimates using inverse sampling weights provided by the NIS.4 Trend weights were used for 2006 through 2011 to adjust for the sampling redesign that was implemented in 2012.4
Among 25 004 243 hospitalizations overall for patients with cancer, 14 095 (0.06%) were opioid-related hospitalizations. Using a linear regression model, we approximated the trend in the overall number of opioid-related hospitalizations from 2006 to 2014 and observed an average increase of 78.9 admissions per year (from 1170 to 1715, P = .01). After adjusting for all-cause hospitalizations, the linear time trend of opioid-related hospitalizations increased on average by 0.003% per year (P = .003). Further decomposition by diagnosis type shows that nonheroin opioid poisoning made up 88.0% of all opioid-related hospitalizations (Figure). Factors associated with opioid-related hospitalizations for patients with cancer included drug abuse (odds ratio [OR], 7.92; 95% CI, 6.95-9.02), depression (OR, 2.34; 95% CI, 2.13-2.58), psychotic disorder (OR, 4.13; 95% CI, 3.66-4.65), white race, younger age, and year of hospitalization (Table). Alcohol abuse was associated with opioid-related hospitalizations, but the association was not significant (OR, 1.15; 95% CI, 0.99-1.35).
Opioid-related hospitalizations among patients with cancer are rare, are increasing at a very low rate over time, and are largely associated with nonheroin opioid poisoning. The characteristics associated with opioid-related hospitalizations among patients with cancer are consistent with established risk factors for opioid abuse in the noncancer population. Prior to prescribing opioids for cancer-related pain, routinely screening patients using standardized tools based on these associated factors (eg, Opioid Risk Tool6) may identify those patients with the greatest risk of an opioid-related hospitalization. Currently, no validated opioid risk screening tools exist specifically for patients with cancer, and little guidance is available on pain management in patients with both cancer and aberrant opioid use behavior.3 Additional research on opioid risk screening and management for patients with combined cancer and substance use disorders is needed.
Accepted for Publication: December 26, 2018.
Corresponding Author: Isaac S. Chua, MD, Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, 450 Brookline Ave, Dana 2016A, Boston, MA 02215-5450 (email@example.com).
Published Online: March 28, 2019. doi:10.1001/jamaoncol.2019.0042
Author Contributions: Dr Lindvall had full access to all of the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Chua, Leiter, Brizzi, Coey, Lindvall.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Chua, Leiter, Lindvall.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Chua, Brizzi, Coey, Mazzola, Lindvall.
Administrative, technical, or material support: Lindvall.
Study supervision: Tulsky, Lindvall.
Conflict of Interest Disclosures: None reported.
Funding/Support: Dr Lindvall was supported by a Junior Faculty Research Award from the National Palliative Care Research Center (NPCRC), New York, NY and a Faculty Development Award from the Gloria Spivak Fund, Boston, MA.
Role of the Funder/Sponsor: The funders were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Create a personal account or sign in to: